ArticleJournal of the American Society of Nephrology : JASN2018
Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy.
Article in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07347769 (Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy), which is not on this map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy
Who cites it
60 citing papers in PubMed, 109 citations in OpenAlex.
- First-In-Human, Randomized, Placebo-Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults.Clinical and translational science · 2025Trial
- Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients.Antimicrobial agents and chemotherapy · 2019Trial
- Role of BK Virus CTLs in the Treatment of BK Virus-Associated Nephropathy in Kidney-Transplant and Hematopoietic Cell Transplant Recipients.Transplant infectious disease : an official journal of the Transplantation SocietyTrial
- Early BK Polyomavirus-Specific Immunity and Viral Clearance.Kidney international reports · 2026Article
- Insight Into Current BK Polyomavirus Research Efforts: BK Day Meeting 2024.Transplantation · 2026Article
- Unveiling Donor-Derived BKPyV DNAemia Through Analysis of Contralateral Kidney Transplant Recipients.Biomedicines · 2026Article
- The Burden of BK Polyomavirus in Pediatric Renal Transplantation: A Belgian Experience.Biomedicines · 2026Article
- Article
- Case Report: Late-onset BK polyomavirus-associated nephropathy in kidney transplant recipients: two cases and insights into underlying mechanisms.Frontiers in medicine · 2026Review
- BK Polyomavirus in Renal Transplantation: Virological Notes for Monitoring and Diagnosis.Biomolecules · 2025Review
- Broadly neutralizing human monoclonal antibodies against BK polyomavirus genotypes.The Journal of general virology · 2025Article
- Development of BK polyomavirus-associated nephropathy risk prediction in kidney transplant recipients.Renal failure · 2025Article
- Updates in the Diagnosis and Treatment of BK Viraemia in Kidney Transplant Recipients: Current and Future Insights.Journal of clinical medicine · 2025Review
- Article
- NaCl and urea modulate CD8+ T cell survival, renal accumulation, and response to BK virus.JCI insight · 2025Article
- Review
- Urine-derived renal tubular epithelial cells resemble functional characteristics of professional antigen-presenting cells and can directly induce BKV-specific T cell responses.Journal of nephrology · 2025Article
- Utility of the ELISpot Test to Predict the Risk of Developing BK Polyomavirus Nephropathy in Kidney Recipients, a Multicenter Study.Vaccines · 2025Article
- A highly potent human antibody neutralizing all serotypes of BK polyomavirus.PLoS pathogens · 2025Article
- BK Polyomavirus-associated nephropathy - diagnostic and treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK virus-associated nephropathy (BKVAN) causes renal allograft dysfunction. The current management of BKVAN relies on pre-emptive adaptation of immunosuppression according to viral load monitoring. However, this empiric strategy is not always successful. Therefore, pretransplant predictive markers are needed. In a prospective longitudinal study, we enrolled 168 kidney transplant recipients and 69 matched donors. To assess the value of BKV genotype-specific neutralizing antibody (NAb) titers as a predictive marker for BKV replication, we measured BKV DNA load and NAb titers at transplant and followed patients for 24 months. After transplant, 52 (31%) patients displayed BKV replication: 24 (46%) patients were viruric and 28 (54%) patients were viremic, including 13 with biopsy-confirmed BKVAN. At any time, patients with high NAb titers against the replicating strain had a lower risk of developing BKV viremia (hazard ratio [HR], 0.44; 95% confidence interval [95% CI], 0.26 to 0.73;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.